Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
foroxymithine
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Foroxymithine is a novel, physiologically active substance that has been studied for its antihypertensive properties. In preclinical studies, oral administration of foroxymithine dihydrate effectively reduced blood pressure in spontaneous hypertensive rats. Acute toxicity tests in mice showed low toxicity, with high intravenous doses not causing mortality. Purification of foroxymithine can be achieved through reversed-phase HPLC, and its use as an antihypertensive agent is supported by preclinical efficacy data, although there is no evidence of clinical approval or human development status[4].
- Other names
- foroxymithine dihydrate
Beyond the preview
Go deeper on foroxymithine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on foroxymithine.